Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cancer~  * CNS malignancy allowed with the exception of leptomeningeal carcinomatosis~* Must have painful sensory chemotherapy-induced peripheral neuropathy (CIPN) resulting from prior treatment with single-agent taxane or platinum agents (paclitaxel, docetaxel, nab-paclitaxel, oxaliplatin, cisplatin) (may not have received drugs from both classes)~  * CIPN \> grade 1 as measured by NCI-CTCAE v 4.0~ * Average neuropathic pain score ≥ 4~* Patients with the following illnesses known to cause peripheral neuropathy are eligible, provided they have no evidence of neuropathy from these illnesses:~  * Diabetes mellitus~ * Peripheral vascular disease~ * HIV infection~ * Significant degenerative or familial neurologic disorder known to cause peripheral neuropathy~* No clinical or subclinical neuropathy from nerve compression injuries (i.e., carpal tunnel syndrome, brachial plexopathy, spinal stenosis, or spinal nerve root compression)~PATIENT CHARACTERISTICS:~* AST ≤ 3 times upper limit of normal~* Total bilirubin ≤ normal~* Creatinine clearance \> 30 mL/min~* Not pregnant or nursing~* Able to take oral or enteral medication~* No history of seizure disorder~* No diagnosis of ethanol addiction or dependence within the past 10 years~* No history of narrow-angle glaucoma~* None of the following:~  * History of suicidal thoughts~ * Symptoms of or history of schizophrenia, bipolar disease, or a major depression~ * Serious eating disorder such as bulimia or anorexia where electrolyte imbalance is likely~PRIOR CONCURRENT THERAPY:~* At least 3 months since prior and no concurrent taxane or platinum agent~* At least 14 days since prior and no concurrent monoamine oxidase inhibitors or other antidepressants~* No other prior or concurrent neurotoxic drugs (e.g., vincristine, vinblastine, cytarabine, thalidomide, bortezomib, carboplatin, or procarbazine)~* No concurrent anticonvulsants~* No concurrent B or E vitamin supplementation in doses greater than the recommended daily allowance (RDA)~  * Centrum (standard formula) and One-A-Day essential formula which contain 100% RDA for vitamins B6, E, and B12 allowed~ * Other multivitamins allowed provided they contain no more than 100% RDA of B vitamins and vitamin E~* No concurrent treatment (pharmacologic) for depression

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I/Group A (Duloxetine then Placebo) (Type: EXPERIMENTAL): Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
- Arm II/Group B (Placebo then Duloxetine) (Type: EXPERIMENTAL): Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.

Based on this trial design, predict the completion outcome and termination type (if applicable).